Cited by 574Asthma and respiratory diseasesOccupational exposure and asthmaRespiratory and Cough-Related Research

The DOI matches its Crossref record.

Alternative excitotoxic hypotheses

Albin, Roger L., Greenamyre, J. Timothy·1992·Neurology

Open this paper in CoChat — free account

Abstract

It is known that asthma is a heterogeneous entity whose manifestations vary with age. Our objective was to examine changes in the manifestation of asthma and asthma-related traits in childhood by defining empirically derived childhood asthma phenotypes and examining their transitions over time. To define the phenotypes we used data on respiratory symptoms, healthcare utilisation, medications, spirometry, airway hyperresponsiveness (AHR), exhaled nitric oxide concentration and atopy from a birth cohort recruited on the basis of having a first-degree relative with asthma. Data were acquired at ages 1.5–11.5 years and analysed using latent transition analysis. In a study population of 370 participants, we classified subjects into four phenotypes: 1) nonatopic, few symptoms (prevalence range from 1.5 to 5 years: 52–60%), 2) atopic, few symptoms (3–21%), 3) nonatopic, asthma and rhinitis symptoms (13–35%), and 4) atopic, asthma and rhinitis symptoms (2–14%) in early childhood; and 1) nonatopic, no respiratory disease (prevalence range from 8 to 11.5 years: 41–46%), 2) atopic, no respiratory disease (23–33%), 3) nonatopic, asthma symptoms, no AHR or airway inflammation (8–12%) and 4) atopic asthma (19%) in mid-childhood. Transitioning between phenotypes was common in early childhood, but less common in later childhood. This analysis represents the first attempt to incorporate longitudinal patterns of several manifestations of asthma into a single model to simultaneously define phenotypes and examine their transitions over time. It provides quantitative support for the view that asthma is a heterogeneous entity, and that some children with wheeze and other respiratory symptoms in early life progress to asthma in mid-childhood, while others become asymptomatic.

Integrity signals

Registry

Crossref · 10.1212/wnl.42.4.733

Cites

Statistics

Recomputing p-values needs the paper’s full text.

Claims the paper makes

This paper’s full text isn’t openly available, so its claims and self-check weren’t run. The registry and citation checks still apply.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Sorted by citations

Glutamate uptake
Danbolt, N. C. (2001) · Progress in Neurobiology · doi:10.1016/s0301-0082(00)00067-8 · Cited by 4,227
Aging, energy, and oxidative stress in neurodegenerative diseases
Beal, M. F. (1995) · Annals of Neurology · doi:10.1002/ana.410380304 · Cited by 1,434
Mitochondria and neuronal survival
Nicholls, D. G., & Budd, S. L. (2000) · Physiological Reviews · doi:10.1152/physrev.2000.80.1.315 · Cited by 1,243
Neurochemical and histologic characterization of striatal excitotoxic lesions produced by the mitochondrial toxin 3-nitropropionic acid
Beal, M. F., Brouillet, E., Jenkins, B. G., Ferrante, R. J., Kowall, N. W., Miller, J., Storey, E., Srivastava, R., Rosen, B. R., & Hyman, B. T. (1993) · Journal of Neuroscience · doi:10.1523/jneurosci.13-10-04181.1993 · Cited by 1,026
Glutamate-mediated excitotoxicity and neurodegeneration in Alzheimer?s disease
HYND, M. (2004) · Neurochemistry International · doi:10.1016/j.neuint.2004.03.007 · Cited by 938
Oxidative damage and metabolic dysfunction in Huntington's disease: Selective vulnerability of the basal ganglia
Browne, S. E., Bowling, A. C., Macgarvey, U., Baik, M. J., Berger, S. C., Muquit, M. M. K., Bird, E. D., & Beal, M. F. (1997) · Annals of Neurology · doi:10.1002/ana.410410514 · Cited by 885
A YAC Mouse Model for Huntington’s Disease with Full-Length Mutant Huntingtin, Cytoplasmic Toxicity, and Selective Striatal Neurodegeneration
Hodgson, J., Agopyan, N., Gutekunst, C., Leavitt, B. R., LePiane, F. G., Singaraja, R. R., Smith, D. J., Bissada, N., McCutcheon, K. M., Nasir, J., et al. (1999) · Neuron · doi:10.1016/s0896-6273(00)80764-3 · Cited by 851
“…neurons (Figure 6F). receptor hyperactivity as an early abnormality in theSignificant degeneration was present in the striatum pathogenesis of HD, consistent with the hypothesis ofof the YAC72 2498 mouse and in the YAC72 2511 line excitotoxicity in HD (Albin and Greenamyre, 1992; Coyleat 12 months.”
Result
Why did NMDA receptor antagonists fail clinical trials for stroke and traumatic brain injury?
Ikonomidou, C., & Turski, L. (2002) · The Lancet Neurology · doi:10.1016/s1474-4422(02)00164-3 · Cited by 740
Neurodegenerative disorders in humans: the role of glutathione in oxidative stress-mediated neuronal death
Bains, J. S., & Shaw, C. A. (1997) · Brain Research Reviews · doi:10.1016/s0165-0173(97)00045-3 · Cited by 718
Memantine: a NMDA receptor antagonist that improves memory by restoration of homeostasis in the glutamatergic system - too little activation is bad, too much is even worse
Parsons, C. G., Stöffler, A., & Danysz, W. (2007) · Neuropharmacology · doi:10.1016/j.neuropharm.2007.07.013 · Cited by 724
“For more extensive discussion of these factors (which is not the main aim of this review) the readers should refer to one of the recent reviews focusing on this aspect (Greenamyre, 1991; Albin and Greenamyre, 1992; Delatorre, 1994; Beal, 1995, 2000).”
Background
Early Phenotypic Changes in Transgenic Mice That Overexpress Different Mutants of Amyloid Precursor Protein in Brain
Moechars, D., Dewachter, I., Lorent, K., Reversé, D., Baekelandt, V., Naidu, A., Tesseur, I., Spittaels, K., Haute, C. V. D., Checler, F., et al. (1999) · Journal of Biological Chemistry · doi:10.1074/jbc.274.10.6483 · Cited by 668
Neuroprotection by the Metabolic Antioxidant α-Lipoic Acid
Packer, L., Tritschler, H. J., & Wessel, K. (1997) · Free Radical Biology and Medicine · doi:10.1016/s0891-5849(96)00269-9 · Cited by 639
Functional changes of the basal ganglia circuitry in Parkinson's disease
Blandini, F., Nappi, G., Tassorelli, C., & Martignoni, E. (2000) · Progress in Neurobiology · doi:10.1016/s0301-0082(99)00067-2 · Cited by 605
Behavioral and Anatomical Correlates of Chronic Episodic Hypoxia during Sleep in the Rat
Gozal, D., Daniel, J. M., & Dohanich, G. P. (2001) · Journal of Neuroscience · doi:10.1523/jneurosci.21-07-02442.2001 · Cited by 577
“Thus, long-term hypoxic conditions are associated with profound decrements in NMDA receptor expression, suggesting that NMDA glutamate receptor-expressing cells may have increased vulnerability to hypoxia, possibly via slowly evolving excitotoxicity processes (Albin and Greenamyre, 1992).”
Background
Do defecs in mitochondrial energy metabolism underlie the pathology of neurodegenerative diseases?
Beal, M. F., Hyman, B. T., & Koroshetz, W. J. (1993) · Trends in Neurosciences · doi:10.1016/0166-2236(93)90117-5 · Cited by 574
Time course of early motor and neuropathological anomalies in a knock‐in mouse model of Huntington's disease with 140 CAG repeats
Menalled, L., Sison, J. D., Dragatsis, I., Zeitlin, S. O., & Chesselet, M. (2003) · The Journal of Comparative Neurology · doi:10.1002/cne.10776 · Cited by 528
“…to the external segment of the globus pallidus present earlier signs of neuronal dysfunction than those projecting to the internal segment in patients with HD (Reiner et al., 1988; Albin and Greenamyre, 1992; Sapp et al., 1995) and in HD mice (Luthi-Carter et al., 2000; Menalled et al., 2000).”
Background
Mutant huntingtin directly increases susceptibility of mitochondria to the calcium-induced permeability transition and cytochrome c release
Choo, Y. S. (2004) · Human Molecular Genetics · doi:10.1093/hmg/ddh162 · Cited by 515
Widespread expression of Huntington's disease gene (IT15) protein product
Sharp, A. H., Loev, S. J., Schilling, G., Li, S.-H., Li, X.-J., Bao, J., Wagster, M. V., Kotzuk, J. A., Steiner, J. P., Lo, A., et al. (1995) · Neuron · doi:10.1016/0896-6273(95)90345-3 · Cited by 516
“N-methyI-D-aspartate (NMDA) agonists, in particular, mimic the pattern of cell loss and cell sparing seen in HD (Beal et al., 1986, 1991; Albin and Greenamyre, 1992; Choi, 1992).”
Oxidative stress in Huntington’s disease
Browne, S. E., Ferrante, R. J., & Beal, M. F. (1999) · Brain Pathology · doi:10.1111/j.1750-3639.1999.tb00216.x · Cited by 508
Altered brain neurotransmitter receptors in transgenic mice expressing a portion of an abnormal human Huntington disease gene
Cha, J.-H. J., Kosinski, C. M., Kerner, J. A., Alsdorf, S. A., Mangiarini, L., Davies, S. W., Penney, J. B., Bates, G. P., & Young, A. B. (1998) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.95.11.6480 · Cited by 504
Clinical Experience With Excitatory Amino Acid Antagonist Drugs
Muir, K. W., & Lees, K. R. (1995) · Stroke · doi:10.1161/01.str.26.3.503 · Cited by 503
Chronic mitochondrial energy impairment produces selective striatal degeneration and abnormal choreiform movements in primates.
Brouillet, E., Hantraye, P., Ferrante, R. J., Dolan, R., Leroy‐Willig, A., Kowall, N. W., & Beal, M. F. (1995) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.92.15.7105 · Cited by 485
The corticostriatal projection: from synaptic plasticity to dysfunctions of the basal ganglia
Calabresi, P., Pisani, A., Mercuri, N. B., & Bernardi, G. (1996) · Trends in Neurosciences · doi:10.1016/0166-2236(96)81862-5 · Cited by 462
Dose-dependent lesions of the dopaminergic nigrostriatal pathway induced by instrastriatal injection of 6-hydroxydopamine
Przedbroski, S., Leviver, M., Jiang, H., Ferreira, M., Jackson-Lewis, V. R., Donaldson, D. M., & Togasaki, D. M. (1995) · Neuroscience · doi:10.1016/0306-4522(95)00066-r · Cited by 453
The Neuropharmacological Basis for the Use of Memantine in the Treatment of Alzheimer's Disease
Rogawski, M. A., & Wenk, G. L. (2003) · CNS Drug Reviews · doi:10.1111/j.1527-3458.2003.tb00254.x · Cited by 449
“This scenario has become known as the “weak excitotoxicity” model (2,80).”
Background
Neuroprotective Effects of Creatine and Cyclocreatine in Animal Models of Huntington’s Disease
Matthews, R. T., Yang, L., Jenkins, B. G., Ferrante, R. J., Rosen, B. R., Kaddurah-Daouk, R. F., & Beal, M. F. (1998) · Journal of Neuroscience · doi:10.1523/jneurosci.18-01-00156.1998 · Cited by 431
“Key words: creatine; ATP; oxidative injury; 3-nitrotyrosine; 3-nitropropionic acid; Huntington There is substantial evidence that impairment of energy production may play a role in the pathogenesis of neurodegenerative diseases (Albin and Greenamyre, 1992; Beal, 1992).”
Background
Noradrenergic mechanisms in neurodegenerative diseases: a theory
Marien, M. R., Colpaert, F. C., & Rosenquist, A. C. (2004) · Brain Research Reviews · doi:10.1016/j.brainresrev.2004.02.002 · Cited by 425
Replicating Huntington's disease phenotype in experimental animals
Brouillet, E. (1999) · Progress in Neurobiology · doi:10.1016/s0301-0082(99)00005-2 · Cited by 421
Energy metabolism defects in Huntington's disease and effects of coenzyme Q10
Koroshetz, W. J., Jenkins, B. G., Rosen, B. R., & Beal, M. F. (1997) · Annals of Neurology · doi:10.1002/ana.410410206 · Cited by 405
The NMDA receptor antagonist memantine as a symptomatological and neuroprotective treatment for Alzheimer's disease: preclinical evidence
Danysz, W., & Parsons, C. G. (2003) · International Journal of Geriatric Psychiatry · doi:10.1002/gps.938 · Cited by 404
“An important aspect of this concept is the fact that an increase in glutamate levels per se is not necessarily required, because changes in receptors sensitivity and their overactivation by resting levels of glutamate could also contribute to neuronal death (Albin and Greenamyre, 1992).”
Mechanisms of excitotoxicity in neurologic diseases
Beal, M. F. (1992) · The FASEB Journal · doi:10.1096/fasebj.6.15.1464368 · Cited by 385
Organization of N‐methyl‐D‐aspartate glutamate receptor gene expression in the basal ganglia of the rat
Standaert, D. G., Testa, C. M., Young, A. B., & Penney, J. B. (1994) · The Journal of Comparative Neurology · doi:10.1002/cne.903430102 · Cited by 373
3‐Nitropropionic acid: a mitochondrial toxin to uncover physiopathological mechanisms underlying striatal degeneration in Huntington's disease
Brouillet, E., Jacquard, C., Bizat, N., & Blum, D. L. (2005) · Journal of Neurochemistry · doi:10.1111/j.1471-4159.2005.03515.x · Cited by 371
“These results, combined with the observations indicating an impairment of energy metabolism in patients with HD, suggested that metabolic anomalies in HD could result in the indirect activation of the excitotoxic cascade (Albin and Greenamyre 1992; Beal 1992).”
Result
The neural basis of the complex mental task of meditation: neurotransmitter and neurochemical considerations
Newberg, A. B., & Iversen, J. R. (2003) · Medical Hypotheses · doi:10.1016/s0306-9877(03)00175-0 · Cited by 352
“Glutamate activates N-methyl-D-aspartate receptors (NMDAr), but excess glutamate can kill these neurons through excitotoxic processes (54).”
Background
Riluzole treatment, survival and diagnostic criteria in Parkinson plus disorders: The NNIPPS Study
Bensimon, G., Ludolph, A., Agid, Y., Vidailhet, M., Payan, C., & Leigh, P. N. (2008) · Brain · doi:10.1093/brain/awn291 · Cited by 352
Memantine and Cholinesterase Inhibitors: Complementary Mechanisms in the Treatment of Alzheimer’s Disease
Parsons, C. G., Danysz, W., Dekundy, A., & Pulte, I. (2013) · Neurotoxicity Research · doi:10.1007/s12640-013-9398-z · Cited by 346
“It is probable that this pathological over-activity is due to increased resting glutamate concentrations, as well as increased receptor sensitivity to resting glutamate levels (Albin and Greenamyre 1992; Danysz and Parsons 2003).”
Glutamate and Parkinson’s disease
Blandini, F., Porter, R. H. P., & Greenamyre, J. T. (1996) · Molecular Neurobiology · doi:10.1007/bf02740748 · Cited by 332
Self-citation
Protective effect of encapsulated cells producing neurotrophic factor CNTF in a monkey model of Huntington's disease
Emerich, D. F., Winn, S. R., Hantraye, P., et al. (1997) · Nature · doi:10.1038/386395a0 · Cited by 322
Impaired glutamate transport and glutamate-glutamine cycling: downstream effects of the Huntington mutation
Behrens, P. F. (2002) · Brain · doi:10.1093/brain/awf180 · Cited by 322
“Neuronal loss accompanied by ®brillary gliosis is most obvious in the striatum, where striatal projection neurones are preferentially lost (Albin et al., 1992).”
Background
Going the Extra (Synaptic) Mile: Excitotoxicity as the Road Toward Neurodegenerative Diseases
Armada‐Moreira, A., Gomes, J. I., Pina, C. C., Savchak, O. K., Gonçalves‐Ribeiro, J., Rei, N., Pinto, S., Morais, T. P., Martins, R. S., Ribeiro, F. F., et al. (2020) · Frontiers in Cellular Neuroscience · doi:10.3389/fncel.2020.00090 · Cited by 337
“Other than this classification system for excitotoxicity, this phenomenon can be further categorized as strong or weak excitotoxicity (Albin and Greenamyre, 1992).”
Background
Intermittent Hypoxia Is Associated with Oxidative Stress and Spatial Learning Deficits in the Rat
Row, B. W., Liu, R., Xu, W., Kheirandish, L., & Gozal, D. (2003) · American Journal of Respiratory and Critical Care Medicine · doi:10.1164/rccm.200209-1050oc · Cited by 307
Identification and localization of huntingtin in brain and human lymphoblastoid cell lines with anti-fusion protein antibodies.
Gutekunst, C., Levey, A. I., Heilman, C. J., Whaley, W. L., Yi, H. L., Nash, N. R., Rees, H. D., Madden, J. J., & Hersch, S. M. (1995) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.92.19.8710 · Cited by 305
Altered glutamatergic transmission in neurological disorders: From high extracellular glutamate to excessive synaptic efficacy
Obrenovitch, T. P., & Urenjak, J. (1997) · Progress in Neurobiology · doi:10.1016/s0301-0082(96)00049-4 · Cited by 306
Amino-terminal fragments of mutant huntingtin show selective accumulation in striatal neurons and synaptic toxicity
He, L., Li, S.-H., Johnston, H. M., Shelbourne, P., & Li, X. (2000) · Nature Genetics · doi:10.1038/78054 · Cited by 305
Invited Review: Physiological and pathophysiological responses to intermittent hypoxia
Neubauer, J. A. (2001) · Journal of Applied Physiology · doi:10.1152/jappl.2001.90.4.1593 · Cited by 306
Age‐Dependent Striatal Excitotoxic Lesions Produced by the Endogenous Mitochondrial Inhibitor Malonate
Beal, M. F., Brouillet, E., Jenkins, B. G., Henshaw, R., Rosen, B. R., & Hyman, B. T. (1993) · Journal of Neurochemistry · doi:10.1111/j.1471-4159.1993.tb03633.x · Cited by 297
Mitochondrial dysfunction and oxidative stress in aging and neurodegenerative disease
Albers, D. S., & Beal, M. F. (2000) · Springer eBooks · doi:10.1007/978-3-7091-6781-6_16 · Cited by 298
Group I metabotropic glutamate receptors: implications for brain diseases
Bordi, F., & Ugolini, A. (1999) · Progress in Neurobiology · doi:10.1016/s0301-0082(98)00095-1 · Cited by 294
HD CAG repeat implicates a dominant property of huntingtin in mitochondrial energy metabolism
Seong, I. S., Ivanova, E. V., Lee, J., Choo, Y. S., Fossale, E., Anderson, M., Gusella, J. F., Laramie, J. M., Myers, R. H., Lesort, M. J., et al. (2005) · Human Molecular Genetics · doi:10.1093/hmg/ddi319 · Cited by 291
Parvalbumin and calbindin D‐28k in the human motor system and in motor neuron disease
Ince, P. G., Stout, N., Shaw, P. J., Slade, J. Y., Hunziker, W. H., Heizmann, C. W., & Baimbridge, K. G. (1993) · Neuropathology and Applied Neurobiology · doi:10.1111/j.1365-2990.1993.tb00443.x · Cited by 291
The blood-brain barrier and glutamate.
Hawkins, R. (2009) · American Journal of Clinical Nutrition · doi:10.3945/ajcn.2009.27462bb · Cited by 294
Changes in Cortical and Striatal Neurons Predict Behavioral and Electrophysiological Abnormalities in a Transgenic Murine Model of Huntington's Disease
Laforet, G. A., Sapp, E., Chase, K. O., McIntyre, C., Boyce, F. M., Campbell, M. L., Cadigan, B. A., Warzecki, L., Tagle, D. A., Reddy, P. H., et al. (2001) · Journal of Neuroscience · doi:10.1523/jneurosci.21-23-09112.2001 · Cited by 294
“…neuronal death in HD and other neurodegenerative disorders and may involve alterations in NMDA-type glutamate receptors and a rise in intracellular Ca2 (Coyle and Schwarcz, 1976; McGeer and McGeer, 1976; Choi, 1988; DiFiglia, 1990; Beal et al., 1991; Albin and Greenamyre, 1992; Brown et al., 1997).”
Background
Cellular, Subcellular, and Subsynaptic Distribution of AMPA-Type Glutamate Receptor Subunits in the Neostriatum of the Rat
Bernard, V., Somogyi, P., & Bolam, J. P. (1997) · Journal of Neuroscience · doi:10.1523/jneurosci.17-02-00819.1997 · Cited by 281
“Furthermore, glutamate-induced excitotoxicity has been proposed to be responsible for cell death in neurodegenerative diseases (Young et al., 1988; DiFiglia, 1990; Albin and Greenamyre, 1992).”
BackgroundResult
Transcriptional signatures in Huntington's disease
Cha, J.-H. J. (2007) · Progress in Neurobiology · doi:10.1016/j.pneurobio.2007.03.004 · Cited by 275
Chronic 3-Nitropropionic Acid Treatment in Baboons Replicates the Cognitive and Motor Deficits of Huntington’s Disease
Palfi, S., Ferrante, R. J., Brouillet, E., Beal, M. F., Dolan, R., Guyot, M., Peschanski, M., & Hantraye, P. (1996) · Journal of Neuroscience · doi:10.1523/jneurosci.16-09-03019.1996 · Cited by 259
When more is less: Pathogenesis of glutamine repeat neurodegenerative diseases
Ross, C. A. (1995) · Neuron · doi:10.1016/0896-6273(95)90138-8 · Cited by 260
“An elaboration on this model suggests that metabolically compromised neurons might be more sensitive to excitotoxicity or other forms of toxicity (Albin and Greenamyre, 1992; Beal, 1992).”
Background
The high affinity uptake system for excitatory amino acids in the brain
Danbolt, N. C. (1994) · Progress in Neurobiology · doi:10.1016/0301-0082(94)90033-7 · Cited by 257
Neurodegenerative Diseases – Is Metabolic Deficiency the Root Cause?
Muddapu, V. R., Dharshini, S. A. P., Chakravarthy, V. S., & Gromiha, M. M. (2020) · Frontiers in Neuroscience · doi:10.3389/fnins.2020.00213 · Cited by 255
Protection from mitochondrial complex II inhibition in vitro and in vivo by Nrf2-mediated transcription
Calkins, M. J., Jakel, R. J., Johnson, D. A., Chan, K., Kan, Y. W., & Johnson, J. A. (2005) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0408487101 · Cited by 247
Bioenergetics and glutamate excitotoxicity
Greene, J. G., & Greenamyre, J. T. (1996) · Progress in Neurobiology · doi:10.1016/0301-0082(96)00006-8 · Cited by 250
Self-citation
Therapeutic potential of adenosine A2A receptor antagonists in Parkinson's disease
Xu, K., Bastia, E., & Schwarzschild, M. A. (2004) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2004.10.007 · Cited by 245
A Molecular basis for human hypersensitivity of aminoglyscoside antibiotics
Hutchin, T. P., Haworth, L., Higashi, K., et al. (1993) · Nucleic Acids Research · doi:10.1093/nar/21.18.4174 · Cited by 241
The Energetics of Huntington's Disease
Browne, S. E., & Beal, M. F. (2004) · Neurochemical Research · doi:10.1023/b:nere.0000014824.04728.dd · Cited by 240
“Impaired energy metabolism, resulting from a toxic action of mutant huntingtin, may be detrimental to cells by inducing excitotoxic damage (100,101).”
Background
Altered neurotransmitter receptor expression in transgenic mouse models of Huntington's disease
Cha, J.-H. J., Frey, A. S., Alsdorf, S. A., Kerner, J. A., Kosinski, C. M., Mangiarini, L., Penney, J. B., Davies, S. W., Bates, G. P., & Young, A. B. (1999) · Philosophical Transactions of the Royal Society B Biological Sciences · doi:10.1098/rstb.1999.0449 · Cited by 239
“Indeed, intrastriatal administration of exogenous glutamate receptor agonists, particularly those agents activating the N-methyl-D-aspartate (NMDA) subtype of glutamate receptor, reproduces the neuropathological features of HD (Beal et al. 1986; DiFiglia 1990; Albin & Greenamyre 1992).”
Background
Rationale for and use of NMDA receptor antagonists in Parkinson's disease
Hallett, P. J., & Standaert, D. G. (2004) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2004.04.001 · Cited by 238
The diagnosis of manganese-induced parkinsonism
Cersosimo, M. G., & Koller, W. C. (2005) · NeuroToxicology · doi:10.1016/j.neuro.2005.10.006 · Cited by 234
Impaired Spatial Learning and Hyperactivity in Developing Rats Exposed to Intermittent Hypoxia
Row, B. W., Kheirandish, L., Neville, J. J., & Gozal, D. (2002) · Pediatric Research · doi:10.1203/00006450-200209000-00024 · Cited by 239
Transgenic mice expressing a Huntington's disease mutation are resistant to quinolinic acid-induced striatal excitotoxicity
Hansson, O., Petersén, Å., Leist, M., Nicotera, P., Castilho, R. F., & Brundin, P. (1999) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.96.15.8727 · Cited by 228
Huntington's disease gene: Regional and cellular expression in brain of normal and affected individuals
Landwehrmeyer, G. B., McNeil, S. M., Dure, L. S., Ge, P., Aizawa, H., Huang, Q. M., Ambrose, C. M., Duyao, M. P., Bird, E. D., Bonilla, E., et al. (1995) · Annals of Neurology · doi:10.1002/ana.410370213 · Cited by 222
Enhancement of NMDA responses by group I metabotropic glutamate receptor activation in striatal neurones
Pisani, A., Calabresi, P., Centonze, D., & Bernardi, G. (1997) · British Journal of Pharmacology · doi:10.1038/sj.bjp.0700999 · Cited by 211
“First, ligand binding and in situ hybridization studies have provided evidence for the presence of both NMDA receptors (Monaghan et al., 1989; Albin & Greenamyre, 1992; Landwehrmeyer et al., 1995) and mGluRs in the striatum (Shigemoto et al., 1993; Testa et al., 1994; 1995). mGluR5, a group I,…”
Background
Inhibition of Succinate Dehydrogenase by Malonic Acid Produces an “Excitotoxic” Lesion in Rat Striatum
Greene, J. G., Porter, R. H. P., Eller, R. V., & Greenamyre, J. T. (1993) · Journal of Neurochemistry · doi:10.1111/j.1471-4159.1993.tb03634.x · Cited by 208
Self-citation
α-Lipoic Acid: A Metabolic Antioxidant Which Regulates NF-κB Signal Transduction and Protects Against Oxidative Injury
Packer, L. (1998) · Drug Metabolism Reviews · doi:10.3109/03602539808996311 · Cited by 206
Ultrastructural localization and progressive formation of neuropil aggregates in Huntington's disease transgenic mice
Li, H. (1999) · Human Molecular Genetics · doi:10.1093/hmg/8.7.1227 · Cited by 207
Implants of Encapsulated Human CNTF-Producing Fibroblasts Prevent Behavioral Deficits and Striatal Degeneration in a Rodent Model of Huntington’s Disease
Emerich, D. F., Lindner, M. D., Winn, S. R., Chen, E., Frydel, B. R., & Kordower, J. H. (1996) · Journal of Neuroscience · doi:10.1523/jneurosci.16-16-05168.1996 · Cited by 202
“The symptoms of HD result from this selective vulnerability of neostriatal neurons, possibly because of an endogenous disequilibrium of energy metabolism and excitotoxicity (Parker et al., 1990; Albin and Greenamyre, 1992; Beal, 1992; Wallace, 1992).”
Background
Nitric Oxide Acutely Inhibits Neuronal Energy Production
Brorson, J. R., Schumacker, P. T., & Zhang, H. (1999) · Journal of Neuroscience · doi:10.1523/jneurosci.19-01-00147.1999 · Cited by 200
“…has been postulated to occur in chronic neurological conditions whereby the combination of underlying defects in energy metabolism in neurons, combined with the stress of ongoing glutamate receptor activation, gradually produces neuronal damage or death (Albin and Greenamyre, 1992; Beal, 1995).”
Background
Ginsenosides Rb1 and Rg1 effects on mesencephalic dopaminergic cells stressed with glutamate
Radad, K., Gille, G., Moldzio, R., et al. (2004) · Brain Research · doi:10.1016/j.brainres.2004.06.030 · Cited by 198
Chemotherapy for the Brain: The Antitumor Antibiotic Mithramycin Prolongs Survival in a Mouse Model of Huntington's Disease
Ferrante, R. J., Ryu, H., Kubilus, J. K., D’Mello, S. R., Sugars, K. L., Lee, J.-H., Lu, P., Smith, K., Browne, S. E., Beal, M. F., et al. (2004) · Journal of Neuroscience · doi:10.1523/jneurosci.2599-04.2004 · Cited by 195
“Because mitochondrial dysfunction and impaired energy me - tabolism has been implicated in HD pathogenesis ( Albin and Greenamyre , 1992 ; Beal , 1992 ) , it was also necessary to rule out the possibility that mithramycin protects by modulating MPT .”
Background
Mutant Huntingtin Enhances Excitotoxic Cell Death
Zeron, M. M., Chen, N., Moshaver, A., Lee, A. T. C., Wellington, C. L., Hayden, M. R., & Raymond, L. A. (2001) · Molecular and Cellular Neuroscience · doi:10.1006/mcne.2000.0909 · Cited by 200
Neuronal cell death in Huntington’s disease: a potential role for dopamine
Jakel, R. J., & Maragos, W. F. (2000) · Trends in Neurosciences · doi:10.1016/s0166-2236(00)01568-x · Cited by 199
Expression of Normal and Mutant Huntingtin in the Developing Brain
Bhide, P. G., Day, M., Sapp, E., Schwarz, C., Sheth, A. N., Kim, J., Young, A. B., Penney, J. B., Golden, J. A., D, N. A. M., et al. (1996) · Journal of Neuroscience · doi:10.1523/jneurosci.16-17-05523.1996 · Cited by 197
“Neurodegeneration in HD has been strongly linked to an excitotoxic mechanism mediated through NMDA receptors, either directly or as a secondary event associated with altered metabolism (DiFiglia, 1990; Beal et al., 1991, 1993; Albin and Greenmayre, 1992).”
Background
A further update on the role of excitotoxicity in the pathogenesis of Parkinson’s disease
Ambrosi, G., Cerri, S., & Blandini, F. (2014) · Journal of Neural Transmission · doi:10.1007/s00702-013-1149-z · Cited by 195
3-Nitropropionic acid animal model and Huntington' s disease
Borlongan, C. V., Koutouzis, T. K., & Sanberg, P. R. (1997) · Neuroscience & Biobehavioral Reviews · doi:10.1016/s0149-7634(96)00027-9 · Cited by 194
Glutamate antagonists have different effects on spontaneous locomotor activity in rats
Danysz, W., Essmann, U., Bresink, I., & Wilk, R. (1994) · Pharmacology Biochemistry and Behavior · doi:10.1016/0091-3057(94)90506-1 · Cited by 191
Coenzyme Q10 and nicotinamide block striatal lesions produced by the mitochondrial toxin malonate
Beal, M. F., Henshaw, D. R., Jenkins, B. G., Rosen, B. R., & Schulz, J. B. (1994) · Annals of Neurology · doi:10.1002/ana.410360613 · Cited by 189
Subtype‐Specific Enhancement of NMDA Receptor Currents by Mutant Huntingtin
Chen, N., Luo, T., Wellington, C. L., Metzler, M., McCutcheon, K. M., Hayden, M. R., & Raymond, L. A. (1999) · Journal of Neurochemistry · doi:10.1046/j.1471-4159.1999.0721890.x · Cited by 183
Cystamine Inhibits Caspase Activity
Lesort, M. J., Lee, M., Tucholski, J., & Johnson, G. V. W. (2003) · Journal of Biological Chemistry · doi:10.1074/jbc.m205812200 · Cited by 177
Alzheimer’s disease: Targeting the glutamatergic system
Conway, M. E. (2020) · Biogerontology · doi:10.1007/s10522-020-09860-4 · Cited by 180
Neuroprotective properties of memantine in different in vitro and in vivo models of excitotoxicity
Volbracht, C., van Beek, J., Zhu, C., Blomgren, K., & Leist, M. (2006) · European Journal of Neuroscience · doi:10.1111/j.1460-9568.2006.04787.x · Cited by 175
“…AD are believed not necessarily to depend only on increased glutamate levels per se, but also on increased receptor sensitivity and over-activation by resting levels of glutamate (Albin & Greenamyre, 1992), followed by release of endogenous glutamate (Henneberry et al., 1989; Choi & Rothman, 1990).”
Background
Tissue transglutaminase: a possible role in neurodegenerative diseases
Lesort, M. J., Tucholski, J., Miller, M. L., & Johnson, G. V. W. (2000) · Progress in Neurobiology · doi:10.1016/s0301-0082(99)00052-0 · Cited by 173
Glutamate–glutamine cycling in Alzheimer's disease
WALTON, H., & DODD, P. (2007) · Neurochemistry International · doi:10.1016/j.neuint.2006.10.007 · Cited by 174
“Further specificity of neuronal destruction is evidenced by the targeting of specific cell types within these regions (Hyman et al., 1984; Greenamyre and Young, 1989; Albin and Greenamyre, 1992).”
Background
Neurodegeneration in Methylmalonic Aciduria Involves Inhibition of Complex II and the Tricarboxylic Acid Cycle, and Synergistically Acting Excitotoxicity
Okun, J. G., Hörster, F., Farkas, L. M., et al. (2002) · Journal of Biological Chemistry · doi:10.1074/jbc.m200997200 · Cited by 174
The relationship between excitotoxicity and oxidative stress in the central nervous system
Bondy, S. C., & LeBel, C. P. (1993) · Free Radical Biology and Medicine · doi:10.1016/0891-5849(93)90144-j · Cited by 161
Selective Neuronal Degeneration in Huntington's Disease
Cowan, C. M., & Raymond, L. A. (2006) · Current topics in developmental biology/Current Topics in Developmental Biology · doi:10.1016/s0070-2153(06)75002-5 · Cited by 166
Calpain Is a Major Cell Death Effector in Selective Striatal Degeneration InducedIn Vivoby 3-Nitropropionate: Implications for Huntington's Disease
Bizat, N., Hermel, J., Boyer, F., Jacquard, C., Créminon, C., Ouary, S., Escartin, C., Hantraye, P., Krajewski, S., & Brouillet, E. (2003) · Journal of Neuroscience · doi:10.1523/jneurosci.23-12-05020.2003 · Cited by 163
Update on Parkinson Disease
Siderowf, A. D., & Stern, M. (2003) · Annals of Internal Medicine · doi:10.7326/0003-4819-138-8-200304150-00013 · Cited by 164
Heterogeneous Topographic and Cellular Distribution of Huntingtin Expression in the Normal Human Neostriatum
Ferrante, R. J., Gutekunst, C., Persichetti, F., McNeil, S. M., Kowall, N. W., Gusella, J. F., MacDonald, M. E., Beal, M. F., & Hersch, S. M. (1997) · Journal of Neuroscience · doi:10.1523/jneurosci.17-09-03052.1997 · Cited by 162
“Another hypothesis as to the pathogenesis of HD is that an impairment of energy metabolism may play a critical role by rendering neurons vulnerable to excitotoxicity (Albin and Greenamyre, 1992; Beal, 1992, 1994, 1995).”
Background
Bioenergetic abnormalities in discrete cerebral motor pathways presage spinal cord pathology in the G93A SOD1 mouse model of ALS
Browne, S. E., Yang, L., DiMauro, J.-P., Fuller, S. W., Licata, S. C., & Beal, M. F. (2006) · Neurobiology of Disease · doi:10.1016/j.nbd.2006.01.001 · Cited by 170
Mitochondrial Dysfunction in Parkinson's Disease
Keane, P. C., Kurzawa‐Akanbi, M., Blain, P. G., & Morris, C. M. (2011) · Parkinson s Disease · doi:10.4061/2011/716871 · Cited by 182
“Several mechanisms for excitotoxicity in neurodegenerative conditions have been proposed [50, 51].”
Background
Genetics and molecular biology of Huntington's disease
Albin, R. L., & Tagle, D. A. (1995) · Trends in Neurosciences · doi:10.1016/0166-2236(95)93943-r · Cited by 159
Self-citation
Memantine protects against LPS-induced neuroinflammation, restores behaviorally-induced gene expression and spatial learning in the rat
Rosi, S., Vazdarjanova, A. I., Ramı́rez-Amaya, V., Worley, P. F., Barnes, C. A., & Wenk, G. L. (2006) · Neuroscience · doi:10.1016/j.neuroscience.2006.08.017 · Cited by 158

Authors: Albin, R. L., & Greenamyre, J. T.
Affiliations: University of Michigan (US)
University of Rochester (US)
ORCID: Albin, Roger L.
Greenamyre, J. Timothy
Venue: Neurology
Publisher: Ovid Technologies (Wolters Kluwer Health)
Published: 1992-04
Volume: 42
Issue: 4
Pages: 733-733
ISSN: 0028-3878 (ISSN-L)
1526-632X
DOI: 10.1212/wnl.42.4.733
OpenAlex: W2058176457
Cited by: 574
References: 0
Citations by year: 2026: 1 · 2025: 3 · 2024: 6 · 2023: 3 · 2022: 18 · 2021: 4 · 2020: 12 · 2019: 3 · 2018: 6 · 2017: 7 · 2016: 5 · 2015: 4 · 2014: 10 · 2013: 12 · 2012: 16
FWCI: 14.01
Type: journal article
Language: en
Open access: closed
Locations: Neurology (publishedVersion)
PubMed (publishedVersion)
Funders: National Institutes of Health (5k08ns001300-03, 5k08ns001487-03)
National Institute of Neurological Disorders and Stroke (NS01300, NS 01487)
Topics: Health Sciences › Medicine › Pulmonary and Respiratory Medicine › Asthma and respiratory diseases
Health Sciences › Medicine › Public Health, Environmental and Occupational Health › Occupational exposure and asthma
Health Sciences › Medicine › Pulmonary and Respiratory Medicine › Respiratory and Cough-Related Research
Keywords: asthma phenotypes, childhood asthma, asthma heterogeneity, phenotype transition, atopy, rhinitis, airway hyperresponsiveness, exhaled nitric oxide, wheezing, latent transition analysis, birth cohort
MeSH terms: Acute Disease, Amino Acids, Chronic Disease, Humans, Models, Neurological, Nerve Degeneration, Nervous System Diseases, Neurology, Neurotoxins, Receptors, Cell Surface, Receptors, Amino Acid

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Alternative excitotoxic hypotheses

Abstract

Overview

Integrity signals

Verification

Claims the paper makes

Claims other papers make about this one

Citations

Cited by

Related

Metadata

Record

About these checks